Q. Van Thillo

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

C. Wouters, M. Thomeer, P. Verhamme, 2020, Trials.

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma

S. Ogawa, S. Demeyer, K. Jacobs, 2022, bioRxiv.

Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study

G. Van den Berghe, C. Wouters, P. Verhamme, 2022, Research and Practice in Thrombosis and Haemostasis.

Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

C. Wouters, M. Thomeer, P. Verhamme, 2020, Trials.

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

P. Maes, G. Meyfroidt, N. Van Regenmortel, 2021, European Respiratory Journal.

Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia

Ira W. Deveson, W. Tam, R. Dickins, 2021, Nature Communications.

Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)

W. Janssens, P. Verhamme, C. Pilette, 2022, ERJ Open Research.

Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion

L. Michaux, T. Devos, B. Dewaele, 2023, British journal of haematology.